Luis R. Barreras, M.D., FACP

Dr. Luis Barreras

Board Certified in Medical Oncology

Board Certified in Hematology

Board Certified in Internal Medicine

Luis R. Barreras, M.D., FACP is Board Certified in Medical Oncology, Hematology and Internal Medicine. He is also registered in the State of Florida to certify qualifying patients for medical marijuana use.

PROFESSIONAL EXPERIENCE

Private Practice

1988-present
Broward Oncology Associates
6405 North Federal Hwy. #300B
Ft. Lauderdale, FL 33308

Emergency room physician in class II

1982-1987
Emergency Room

LANGUAGES

English and Spanish

CERTIFICATIONS

1993 Fellow, American College of Physicians
1991 Board Certified, Subspecialty of Oncology
1990 Board Certified, Subspecialty of Hematology
1984 Diplomat, American Board of Internal Medicine

Licensure: State of Florida ME 0041162

ASCO ID: 18635

MEDICAL STAFF PRIVILEGES

Dr. Barreras’ medical staff privileges. Hospitals in Broward County that Dr. Barreras has medical staff privileges.

  • 2003-2004 2 Section Chief of Hematology/Oncology, North Ridge Medical Center
  • 2000-Present Clinical Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology, Nova Southeastern University, College of Osteopathic Medicine
  • 1996-Present Co-Director of Research Cancer Center BGMC
  • 1994-Present Visiting Professor Status, Annenberg Center, CA
  • 1992-1995 President – Oncology South, Inc., Oncology Network
  • 1990-1996 Founding Member and President, Light of the World Clinic, Volunteer Indigent Healthcare Clinic
  • 1990-1992 Chief of Medicine, Imperial Point Medical Center
  • 1987-present Holy Cross Hospital, Fort Lauderdale, FL, Imperial Point Medical Center, Fort Lauderdale, FL, North Broward Medical Center, Deerfield Beach, FL, Broward General Medical Center, Fort Lauderdale, FL

Membership in Professional and Scientific Societies

Doctor Luis Berraras is a member of a number of professional and scientific societies related to internal medicine, hematology and oncology.

  • 2005-2008 Cancer Committee Chairman – Holy Cross Hospital
  • 2005-2008 Member, Holy Cross Hospital CME Committee
  • 2004-2005 Member, FLASCO Program Committee
  • 2003-present Member, ACOSOG
  • 2003-present Member, GOG
  • 1998-present Member, AHCA Bone Marrow Advisory Group
  • 1996-present Cancer Diagnostic and Prevention Medical Advisor for Holy Cross Hospital’s Women’s
  • Health & Resource Ctr.
  • 1996-present Professional Advisory Board Member, Gilda’s Society
  • 1996-present Member, International Society of Hematology
  • 1996-present Member, The Best Doctors in America
  • 1996-present Participation in AHCA Expert Witness Program
  • 1995-present Board Member, Hispanic Unity
  • 1993-present Fellow American College of Physicians
  • 1993-present FLASCO Member
  • 1993-present Member, American Society of Clinical Oncology
  • 1991-1994 Delegate, District C Florida Medical Association and Young Physicians Section
  • 1991-1993 Medical Advisor, American Cancer Society
  • 1990-present Caducean Society Member
  • 1990-present Cancer and Leukemia Group B-Investigator #2798
  • 1989-present American Society of Hemophilia
  • 1987-present Member, Florida Medical Association
  • 1986-present Member, American College of Physicians
  • 1984-present American Society of Hematology
  • 1981-1986 Associate Member, American College of Physicians

RESEARCH EXPERIENCE

Research experience with Dr. Barreras as the Principal Investigator

2011

  • Connect™ CLL Registry: The Chronic Lymphocytic Leukemia Disease Registry, Celgene
  • BI 1200.75 LUX BRT Trial: An open-label, randomized Phase III Trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment. Boehringer Ingelheim
  • CA225-346-030: A single arm multicenter Phase II safety study of Cisplatin and Vinorelbine in combination with Cetuximab as first-line treatment for patient with advanced/metastatic NSCLC. Bristol-Myers Squibb Company

2010

  • KLT-PANC-001: A randomized dose escalation, safety, and exploratory efficacy study of Kaglaite injection plus gemcitabine (G+K) versus gemcitabine in patients with advanced pancreatic cancer. KangLaiTe, USA
  • OGX-011-10 “SATURN STUDY”: A randomized, placebo-controlled, double blind, Phase III Study evaluating the clinical benefit of adding Custirsen to Docetaxel re-treatment/prednisone as an option for 2nd line therapy in men with castrate resistant prostate cancer Oncogenex Technologies, Inc.
  • Connect™ MM Registry: An observational study designed to assess clinical and HRQoL outcomes in patients presenting with newly diagnosed MM [multiple myeloma] by comparing the effectiveness associated with common regimens. Celgene
  • FISCO Registry: A 5 year, prospective, non-interventional multicenter registry in sickle cell disease patients. Novartis

2009

  • EC-FV-04: A randomized Phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination, vs. PLD alone, in subjects with platinum-resistant ovarian cancer. Endocyte, Inc.
  • ACO11L08: A multi-center randomized Phase IIB study of Cetuximab (Erbitux®) in combination with platinum-based chemotherapy as first line treatment of patients with recurrent or advanced non-small cell lung cancer (NSCLC) Accelerated Community Oncology Research Network

2008

  • MORE Registry: A prospective, non-interventional multicenter registry in iron overloaded lower-risk myelodysplastic patients. Novartis
  • AP23573-07-302: A pivotal trail to determine the efficacy and safety of AP23573 when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas. ARIAD Pharmaceuticals

2007

  • EFC 6193 – TROPIC Study: A randomized, open label, multi-center study of XRP6258 at 25 mg/m2 in combination with prednisone every 3 wks compared to mitoxantrone in combination w/prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated w/a Taxotere-containing regimen. Sanofi Aventis
  • AMP4074 – NSCLC: A randomized, double blind, Phase II trial of Paclitaxel + carboplatin + bevacizumab with or without APOMAB in patients with previously untreated, advanced stage NSCLC. Genentech
  • A6181087 – NSCLC: A multi-center, randomized, double-blind, controlled Phase III study of efficacy and safety study of sunitinib (SUO11248) in patients w/advanced metastatic NSCLC with erlotinib. Pfizer
  • A6101099 – BRT: A randomized, Phase III study of sunitinib in combination w/capecitabine compared with CAP in patients w/previously treated BRT cancer. Pfizer
  • DOSE REGISTRY: Anemia observational study of dosing and outcomes of erythropoiesis-stimulating therapies. Ortho Biotech
  • PGT 307 – LUNG IN WOMEN ONLY: Paclitaxel poliglumex (CT-2103)/Carboplatin vs. Paclitaxel/carboplatin for the treatment of chemotherapy-naïve advanced non-small cell lung cancer (NSCLC) in women with estradiol 30pg/mL. CTI
  • PIX 203 – RAPID TRIAL: Phase II, Randomized, Multicenter, Comparative Trial of cyclophosphamide, doxorubicin, Vincristine, prednisone, + ritiximab (CHOP-R) and cyclophosphamide, pixantrone, Vincristine, prednisone + ritiximab (CPOP-R) in Patients w/Diffuse Large B-cell Lymphoma. CTI
  • EGF 104383: A Randomized, Double blind, Placebo-controlled, Multicenter, Phase III Study Comparing Activity of Paclitaxel + trastuzumab + lapatinib to Paclitaxel + trastuzumab + placebo in Women w/ErbB2 Overexpressing Metastatic BRT cancer. Glaxo Smith Kline

2006

  • NOVARTIS OPTIMIZE 2: A prospective, randomized, double-blinded, stratified, placebo-controlled, multi-center, 3-arm trial of the continued efficacy and safety of Zometa (every 4 wks vs. every 12 wks vs. placebo) in patients w/documented bone metastases from breast cancer. Novartis
  • UPCI 04-094: Phase III Trial of Adjuvant vs. Neo-adjuvant Chemotherapy w/cisplatin + Docetaxel for Patients w/early Stage NSCLC. University of Pittsburgh
  • CT-2103 (PIONEER) Study: Phase III Open Label Study of Paclitaxel poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Woman w/Chemo Naïve Advanced NSCLC who are PS 2. CTI
  • CPX-1: Phase II Chelator Study of CPX-1 (irinotecan Hcl: floxuridine) liposome Injection in Patients w/advanced Colorectal Cancer. Celator
  • Protocol 20050237: A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP). Amgen
  • BMS CA225009: A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab or Taxane/Carboplatin as First-Line Treatment for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer. Bristol-Myer Squib
  • 011-007: A Phase III, Randomized, Open-Label Study Evaluation DN-101 in Combination with Docetaxel in Androgen-Independent Prostrate Cancer (AIPC) (ASCENT-2). Novacea

2005

  • TPU-S1301: An Open-Label, Multicenter, Randomized Phase III Study of S-1 in Combination with Cisplatin Compared against 5FU in Combination with Cisplatin in Patients with Advanced Gastric Cancer Previously Untreated with Chemotherapy for Advanced Disease. Taiho
  • DOXIL-BCA-3001: A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel for the Treatment of Advanced Breast Cancer. J&J PR&D

2004

  • PR03-27-063: A Double-Blind Randomized Study to Evaluate the Response Rate of Procrit® (Epoetin Alfa) vs. Placebo in Anemic Patients with Cancer and Persistent Chemotherapy Induced Myelosuppression. Ortho Biotech
  • PR03-27-064: A Randomized Open-Label Study of Procrit® (Epoetin Alfa) at 60,000 Units or 80,000 Units Every Two Weeks in Anemic Patients with Cancer Receiving Chemotherapy. Ortho Biotech
  • Lung1Pilot: Pilot Study of Lung Function and Chemotherapeutic Treatment of NSCLC and Preliminary Validation of Lung Cancer Survey Including a Global Patient Self-Reported Lung Symptom Question. Astra Zeneca (Quantros, Inc)
  • XRP9881B-3001: Phase III Study of XRP9881 vs. capecitabine (Xeloda®) in Patients with Metastatic BRT Cancer After Failure of Taxanes. Aventis
  • CA225014 (EXPLORE): Phase III Study of Cetuximab, Oxaliplatin, 5FU and LCV vs. Oxaliplatin, 5FU and LCV in Patient with Previously Treated Metastatic, EGFR-positive Colorectal Carcinoma. Bristol Myers Squibb
  • TLK286.3020: Phase III Study of TLK286 vs. gefitinib (Iressa®) as Third-Line Therapy in Locally Advanced or Metastatic NSCLC. Telik, Inc.

2003

  • PR03-27-007An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of Procrit® (Epoetin Alfa) in the Treatment of Patients with Cancer and Chemotherapy Induced Anemia. Ortho Biotech

2002

  • ANC Study Group Registry: A Prospective Study of Neutropenic Complications Awareness of Neutropenia in Chemotherapy Study Group Albany Medical Center-Dr. Gary Lyman

2001

  • 001-015 Phase II Study of SGN-15 (cBR96-Doxorubicin Immunoconjugate) Combined with Taxotere® in Patients with Hormone Refractory Prostate Cancer. Seattle Genetics
  • H2251n Phase IV Community-based study for clinical outcomes in patients with HER2 gene-amplified metastatic BRT cancer treated with 1st line Herceptin® in combination with a taxane. Genentech
  • PR 00-27-012 Phase IV Open Label Study of PROCRIT
    (Epoetin alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer. Ortho Biotech
  • SEQol-Study of ELLENCE* Quality of Life Phase III Randomized Study of epirubicin/cyclophosphamide followed by taxane (sequential chemotherapy) vs epirubicin/taxane (concurrent chemotherapy) as adjuvant treatment for operable, node positive breast cancer. Pharmacia

2000

  • AG 3340-030 Phase IIII Compassionate Use Access to the Matrix. Agouron Pharmaceuticals
  • An Open-Label Study of a New Hematin Product-M00-246. Abbott Laboratories
  • NAFTA Trial – Phase III Study of Tamoxifen vs Toremifene. Roberts Pharmaceutical (University of Louisville under grant from Orion Corp.)
  • M66104C – Phase IIIB Study Metastatic Breast Cancer. Xeloda and Taxol as 1st or 2nd line therapy. Roche

1999

  • VIN 40018 -Phase IV Study (NSCLC), Glaxo Wellcome
  • The ILIAD Trial – Metastatic Renal Cell Carcinoma, Chiron Corporation

1998

  • Procrit Study. Ortho Biotech
  • AG 3340 MMP Phase II Study (LUNG & PROSTATE). Agouron Pharmaceuticals

1997

  • PI for RTOG Protocol. Broward General Medical Center
  • Oral Ondansetron Study. Randomized Dose Comparison. Glaxo Wellcome. (Published 1999)
  • Daunoxome, Phase II Study. (BRT & NHL). NeXstar

1996

  • Topotecan, Open Label Study. Smith Kline Beecham
  • Taxotere, Phase III Study. Rhone-Poulenc Rorer
  • Gemcitabine, IND Treatment Protocol. Lilly
  • Oxycontin, Phase III Analgesic Study. Purdue Frederick. Itasetron vs. Ondansetron, Phase III Study. Boehringer

1995

  • Alopecia, Phase II Study. University of Miami
  • Procrit, Phase III Anemia Related Study. Ortho Biotech. Navelbine, IND Study. Burroughs Wellcome

1990

  • CCOP & Comprehensive Cancer Research Group, Inc.

PUBLICATIONS

Publications by Doctor Luis Berraras:

  • Green, D, Barreras, LR, et al., (1985): A double blind, placebo-controlled trial of fish oil concentrate (Maxepa) in stroke patients. Stroke 16 (4): 706-709
  • Barreras, LR, Ahn, YS & Harrington, WJ, (1985): Successful use of cyclosporin-A in severe aplastic anemia. American Society of Clinical Hematology. 31 (abstract).
  • Barreras, LR, Sridhar, KS, et al., (1991): Bronchoesophageal fistula in recurrent aerodigestive cancers following chemotherapy. Cancer 61 (2): 247-251
  • Barreras, LR (1992): Use of Interferon/5-FU for hormone resistant prostate cancer. Unpublished.
  • Kori, SH, et al., Barreras, LR, (1998): Purdue Pharma study on the clinical use of around the clock therapy with CR Oxycodone in opioid-naïve patients. (Abstract), 9th World Congress on Pain, Vienna, Austria, August 22-27, 1999
  • Lilenbaum, R, Cano, R, Schwartz, M, Seigel, L, Lutzky, J, Lewis, M, Krill, E, Barreras, LR, (1999): Gemcitabine and Navelbine in Advanced Non-small Cell Lung Cancer: A Phase II Study, Cancer 88 (3): 557-562

EDUCATION

  • 1986-1987 Fellowship in Oncology, University of Miami, Miami, FL
  • 1984-1986 Fellowship in Hematology, University of Miami, Miami, FL
  • 1981-1984 Internship & Residency in Internal Medicine, Northwestern Memorial Hospital, Northwestern University, Chicago, IL
  • 1981-1982 Intern, Northwestern Memorial Hospital, Northwestern University, Chicago, IL
  • 1977-1981 M.D., University of Miami, Miami, FL
  • 1972-1976 B.S., University of Florida, Gainesville, FL

Academic Appointments

  • 2003-2004 Clinical Assistant Professor Department of Internal Medicine, Division of Hematology/Oncology Nova Southeastern University College of Osteopathic Medicine
  • 2000-present Clinical Assistant Professor, Department of Internal Medicine, Division of Hematology/Oncology, Nova Southeastern University, College of Osteopathic Medicine
  • 1996-present Co-Director of Research Cancer Center BGMC
  • 1994-present Visiting Professor Status, Annenberg Center, CA
  • 1992-1995 President – Oncology South, Inc., Oncology Network
  • 1990-1996 Founding Member and President, Light of the World Clinic, Volunteer Indigent Healthcare Clinic
  • 1990-1992 Chief of Medicine, Imperial Point Medical Center